SOLARA

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Jan 22, 2025 → Oct 25, 2026

Cited window

Oct 24, 2025 → Oct 8, 2026

Retrieved

Oct 29, 2026

Title

A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)

Registry

NCT06706076

Study IDs

BH-30643-01

Sponsor

BlossomHill Therapeutics

Design

Phase 1/Phase 2 · Interventional, non randomized, single group

Status

Recruiting

Enrollment

675 estimated

Registered

2024-11-26

Start

2025-01-09 actual

Primary completion

2029-01-31 estimated

Primary endpoint

Dose-limiting toxicities (DLTs) (Phase 1, Dose Escalation)

Interventions

3 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –2 matching sources (2 X threads) could not be read and are not included.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –51 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits apply, so some matching discussion may be missing.
• –Thirty-four potentially relevant discussions that did not name the trial were not read, two sources could not be read, and multiple passages were not fully assessed. Absence of commentary in a topic should therefore not be interpreted as absence of clinician concern.
• –The material mixes clinician-attributed posts, sponsor statements, organizations, investment-oriented accounts and unidentified spoken commentary. Repeated announcements and reposts are not additional independently expressed clinical views.
• –Clinical roles are not established for several named authors. Professional identifiers and affiliations provide background only; they do not establish who spoke an unidentified passage or increase the weight of an opinion.
• –No full results publication or protocol document was available in the sources reviewed. No exact product label was identified for BH-30643 alone or with carboplatin/pemetrexed, so commentary cannot substitute for detailed methods, adjudicated safety information or regulatory documentation.
• –Response estimates and safety percentages refer to different data summaries, populations, doses and event categories. Their differences do not establish a temporal trend, contradiction or change of mind.
• –Several BH-30643 discussions never name SOLARA. They are included for their relevance to the same clinical decision and are identified by their stated setting, rather than treated as additional SOLARA analyses.
• –The episode gives inconsistent FDA-meeting dates. Neither date is selected as confirmed, and development plans, accelerated-approval aims and analyst success assumptions remain prospective.

How reports are built and checked: Methods.

Last checked for new commentary Oct 29, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "SOLARA" (NCT06706076), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "solara-06706076". If you cannot make requests, read https://www.erudio.com/reports/solara-nct06706076.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT06706076", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct06706076 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/solara-nct06706076.json
curl https://www.erudio.com/reports/solara-nct06706076.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "solara-06706076" })